As part of the agreement, Zurich headquartered DKSH will gain an exclusive license to register and commercialize these seven generic formulations from various therapeutic areas like diabetology, cardiology, oncology and immunology, which will be sold under Biocon's brand.
"This collaboration will enable us to address the growing patient needs for affordable access to high-quality generics for chronic diseases and expand our commercial footprint in this region," said Siddharth Mittal, CEO & Managing Director, Biocon, with annual revenues of 837.5 million U.S. dollars. "Together with Biocon Pharma, we can help a lot of patients in Asia who require advanced therapies for chronic diseases."
Colombia Últimas Noticias, Colombia Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Fuente: staronline - 🏆 4. / 75 Leer más »